KCT0001111招募中未知
A Single-Arm, Multicenter, Open-Label, Phase 2 Study ofGemcitabine-Cisplatin Chemotherapy Plus Necitumumab(IMC-11F8) in the First-Line Treatment of Patients WithStage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly Korea0 个研究点目标入组 5 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •Key Inclusion Criteria
- •- Histologically or cytologically confirmed squamous Non-Small Cell Lung Cancer
- •- Stage IV disease at time of study entry based on American Joint Committee on Cancer 7th edition
- •- Measurable disease at time of study entry as defined by RECIST(Response Evaluation Criteria in Solid Tumors)1.1
排除标准
- •Key Exclusion Criteria
- •- Nonsquamous Non-Small Cell Lung Cancer
- •- Prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies
- •targeting the EGFR, vascular endothelial growth factor (VEGF), or VEGF receptor
- •- Previous chemotherapy for NSCLC
- •- Major surgery or received any investigational therapy in the 4 weeks prior to study enrollment
- •- Chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions,
- •which is allowed)
- •- Brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants(patients who have undergone previous radiotherapy for brain metastases, who are now nonsymptomatic and no longer require treatment with steroids or anticonvulsants, are eligible)
研究者
相似试验
进行中（未招募）
不适用
A Study in advanced squamous non small cell lung cancerEUCTR2012-003201-96-ESilly S.A.70
进行中（未招募）
1 期
A Study of nab®-Paclitaxel (Abraxane®) and Carboplatin plus Necitumumab (LY3012211) in Patients with Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 19.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002071-96-GREli Lilly and Company50
进行中（未招募）
不适用
A Study in advanced squamous non small cell lung cancerEUCTR2012-003201-96-NLEli Lilly and Company70
已完成
2 期
A Single-Arm, Multicenter, Open-Label, Phase 2 Study of;Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab;(IMC-11F8) in the First-Line Treatment of Patients With;Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)advance squamous cell NSCLC / specific type of lungcancer1003866610029107NL-OMON40000Eli Lilly7
进行中（未招募）
1 期
A Study of nab®-Paclitaxel (Abraxane®) and Carboplatin plus Necitumumab (LY3012211) in Patients with Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 19.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002071-96-ESilly, S.A.50